证券代码：301290 证券简称：东星医疗 公告编号：2024-063 江苏东星智慧医疗科技股份有限公司 第四届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 江苏东星智慧医疗科技股份有限公司（以下简称"公司"）第四届董事会第二 次会议于 2024 年 8 月 15 日上午 10:00 在公司会议室以现场的方式召开。本次会 议通知已于 2024 年 8 月 5 日通过邮件的方式送达全体董事。本次会议应出席董 事 7 人，实际出席董事 7 人。会议由董事长万世平先生召集并主持，公司监事、 高级管理人员列席了本次董事会。本次会议的召集、召开和表决程序符合《公司 法》等有关法律法规及《公司章程》的相关规定。 二、董事会会议审议情况 经各位董事认真审议，形成了如下决议： （一）审议通过《关于公司<2024 年半年度报告>全文及摘要的议案》 根据《公司法》等法律、法规、规范性文件及《公司章程》的规定，结合公 司 2024 年半年度实际经营情况，公司编制了《2024 年半年度报告》全文及其摘 要。 经审核，董事会认为：公司 ...

编制单位：江苏东星智慧医疗科技股份有限公司 单位：万元 江苏东星智慧医疗科技股份有限公司 2024 年半年度非经营性资金占用及其他关联资金往来情况汇总表 | | | 占用方与上市公 | 上市公司核算 | 年期初 2024 | 年半年度 2024 占用累计发生 | 年半年 2024 | 2024年半年 | 年半年 2024 占用形 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | | | | | 度占用资金的 | 度偿还累计 | 期末占用资 | 占用性质 | | | | 司的关联关系 | 的会计科目 | 占用资金余额 | 金额 | | | 成原因 | | | | | | | | （不含利息） | 利息(如有) | 发生金额 | 金余额 | | | 控股股东、实际控制 | | | | | | | | | | | 人及其附属企业 | | | | | | | | | | | 小计 | - | - | - | | | | | - | - | | 前控股股东、实际控 | | | | | | | ...

董事会关于2024年半年度募集资金存放与使用情况专项报告 证券代码：301290 证券简称：东星医疗 公告编号：2024-068 江苏东星智慧医疗科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集 资金管理和使用的监管要求（2022 年修订）》（证监会公告〔2022〕15 号）、 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 以及《深圳证券交易所创业板上市公司自律监管指南第 2 号——公告格式》的相 关规定，江苏东星智慧医疗科技股份有限公司（以下简称"公司"）就 2024 年 半年度募集资金存放与使用情况作如下专项报告： 一、募集资金基本情况 （一）实际募集资金金额、资金到位情况 经中国证券监督管理委员会证监许可[2022] 1922 号文《关于同意江苏东星 智慧医疗科技股份有限公司首次公开发行股票注册的批复》核准，由主承销商华 泰联合证券有限责任公司向公众投资者发行人民币普通股（A 股）25,043,334 股， 发行价格为每股 44.09 元 ...

北京市天元律师事务所 关于江苏东星智慧医疗科技股份有限公司 2023 年限制性股票激励计划调整授予价格及 作废部分限制性股票的 法律意见 北京市天元律师事务所 北京市西城区金融大街 35 号国际企业大厦 A 座 509 单元 邮编：100033 北京市天元律师事务所 关于江苏东星智慧医疗科技股份有限公司 致：江苏东星智慧医疗科技股份有限公司 北京市天元律师事务所（以下简称本所）接受江苏东星智慧医疗科技股份有 限公司（以下简称公司或东星医疗）的委托，担任公司 2023 年限制性股票激励 计划（以下简称本次激励计划）的专项中国法律顾问，并就本次激励计划调整授 予价格（以下简称本次调整）及作废部分限制性股票事项（以下简称本次作废） 出具法律意见。 本所及经办律师依据《中华人民共和国公司法》（以下简称《公司法》）、《中 华人民共和国证券法》（以下简称《证券法》）、《律师事务所从事证券法律业务管 理办法》《上市公司股权激励管理办法》（以下简称《管理办法》）、《深圳证券交 易所创业板股票上市规则》（以下简称《上市规则》）、《深圳证券交易所创业板上 市公司自律监管指南第 1 号——业务办理》等法律、法规和中国证券监督管理委 ...

江苏东星智慧医疗科技股份有限公司（以下简称"公司"）第四届监事会第 二次会议于 2024 年 8 月 15 日下午 14:00 在公司会议室以现场方式召开。本次会 议通知已于 2024 年 8 月 5 日通过邮件的方式送达全体监事。本次会议由监事会 主席朱慧玲主持，会议应出席监事 3 人，实际出席监事 3 人。公司董事会秘书列 席会议。本次会议的召开符合有关法律、行政法规、部门规章、规范性文件和《公 司章程》的规定。 证券代码：301290 证券简称：东星医疗 公告编号：2024-064 江苏东星智慧医疗科技股份有限公司 第四届监事会第二次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 具体内容详见公司同日于巨潮资讯网（www.cninfo.com.cn)披露的《董事会 关于 2024 年半年度募集资金存放与使用情况专项报告》。 二、监事会会议审议情况 与会监事经过审议，表决通过了以下议案： （一）审议通过《关于公司<2024 年半年度报告>全文及摘要的议案》 经审议，监事会认为：公司编制的《2024 年半年度报告》全文及 ...

Part I Important Notice, Table of Contents and Definitions [Important Notice](index=2&type=section&id=Important%20Notice) The board and management assure report accuracy and completeness, with financial statements verified, and the company plans no cash dividends or bonus shares - The company's board of directors, supervisory board, and senior management guarantee the truthfulness, accuracy, and completeness of the semi-annual report, assuming individual and joint legal responsibility[2](index=2&type=chunk) - Company head Wan Shiping, chief accountant Gong Aiqin, and head of accounting department Xu Hailan declare the financial report is true, accurate, and complete[2](index=2&type=chunk) - The company plans not to distribute cash dividends, bonus shares, or convert capital reserves into share capital[2](index=2&type=chunk) [Table of Contents](index=3&type=section&id=Table%20of%20Contents) This section outlines the report's ten main chapters, providing a comprehensive structural overview for investors - The report comprises ten main chapters, covering important notices, company profile, management discussion and analysis, corporate governance, environmental and social responsibility, significant matters, share changes and shareholder information, preferred shares, bonds, and financial reports[3](index=3&type=chunk) [List of Reference Documents](index=4&type=section&id=List%20of%20Reference%20Documents) This section lists the report's reference documents and their storage location, ensuring information accessibility - Reference documents include signed and sealed financial statements, original drafts of publicly disclosed documents, original semi-annual report texts, and other relevant materials[4](index=4&type=chunk) - The aforementioned filed documents are available at the company's Board of Directors Office[4](index=4&type=chunk) [Definitions](index=5&type=section&id=Definitions) This section defines key terms, including company details, reporting periods, competitors, and medical device classifications, to enhance report comprehension - The reporting period refers to January 1, 2024, to June 30, 2024, and the prior year period refers to January 1, 2023, to June 30, 2023[5](index=5&type=chunk) - The company's main competitors include well-known domestic and international medical device companies such as Johnson & Johnson, Medtronic, Inc., Mindray (Shenzhen Mindray Bio-Medical Electronics Co., Ltd.), and Becton, Dickinson and Company[5](index=5&type=chunk) - Key business-related terms such as medical devices, Class III medical devices, Class II medical devices, Class I medical devices, high-value consumables, low-value consumables, staplers, endoscopes, trocars, CE certification, and FDA are defined in detail[6](index=6&type=chunk) Part II Company Profile and Key Financial Indicators This section provides an overview of the company's basic information and key financial performance metrics [I. Company Profile](index=7&type=section&id=I.%20Company%20Profile) This section provides an overview of the company's basic information, including stock details and legal representative - The company's stock abbreviation is "Dongxing Medical," stock code "301290," listed on the Shenzhen Stock Exchange[7](index=7&type=chunk) - The company's legal representative is Wan Shiping[7](index=7&type=chunk) [II. Contact Person and Contact Information](index=7&type=section&id=II.%20Contact%20Person%20and%20Contact%20Information) This section provides contact details for the Board Secretary and Securities Affairs Representative for investor communication - The Board Secretary's name is Gong Aiqin, contact address is No. 24-4 Changyang Road, Wujin District, Changzhou City, Jiangsu Province, phone 0519-86632199, email gongaiqin@dx-med.com[8](index=8&type=chunk) [III. Other Information](index=7&type=section&id=III.%20Other%20Information) The company's contact information, disclosure details, and registration status remained unchanged during the reporting period - The company's registered address, office address, website, and email remained unchanged during the reporting period[9](index=9&type=chunk) - Information disclosure and storage locations remained unchanged during the reporting period[10](index=10&type=chunk) - The company's registration status remained unchanged during the reporting period[11](index=11&type=chunk) [IV. Key Accounting Data and Financial Indicators](index=8&type=section&id=IV.%20Key%20Accounting%20Data%20and%20Financial%20Indicators) This section presents key accounting data and financial indicators, showing revenue growth but a decline in net profit and EPS compared to the prior year Key Accounting Data and Financial Indicators Year-on-Year Change | Indicator | Current Reporting Period (RMB) | Prior Year Period (RMB) | Year-on-Year Change | | :--- | :--- | :--- | :--- | | Operating Revenue | 213,553,049.86 | 201,802,103.61 | 5.82% | | Net Profit Attributable to Shareholders of Listed Company | 47,679,809.37 | 50,034,885.79 | -4.71% | | Net Profit Attributable to Shareholders of Listed Company After Deducting Non-Recurring Gains and Losses | 30,596,502.81 | 32,939,106.31 | -7.11% | | Net Cash Flow from Operating Activities | 70,317,683.91 | 64,035,419.50 | 9.81% | | Basic Earnings Per Share (RMB/share) | 0.48 | 0.50 | -4.00% | | Diluted Earnings Per Share (RMB/share) | 0.48 | 0.50 | -4.00% | | Weighted Average Return on Net Assets | 2.12% | 2.27% | -0.15% | | **Amount at End of Current Reporting Period (RMB)** | **Amount at End of Prior Year (RMB)** | **Change from Prior Year-End to Current Period-End** | | | Total Assets | 2,373,152,059.47 | 2,393,581,909.51 | -0.85% | | Net Assets Attributable to Shareholders of Listed Company | 2,197,841,813.21 | 2,238,716,685.61 | -1.83% | [V. Differences in Accounting Data Under Domestic and Overseas Accounting Standards](index=8&type=section&id=V.%20Differences%20in%20Accounting%20Data%20Under%20Domestic%20and%20Overseas%20Accounting%20Standards) The company reports no differences in net profit or net assets between domestic and international accounting standards during the period - The company's financial reports for the reporting period show no differences in net profit and net assets when compared between International Accounting Standards and Chinese Accounting Standards[13](index=13&type=chunk) - The company's financial reports for the reporting period show no differences in net profit and net assets when compared between overseas accounting standards and Chinese Accounting Standards[13](index=13&type=chunk) [VI. Non-Recurring Gains and Losses and Amounts](index=8&type=section&id=VI.%20Non-Recurring%20Gains%20and%20Losses%20and%20Amounts) This section itemizes non-recurring gains and losses for the period, totaling **RMB 17,083,306.56**, with explanations for key items Non-Recurring Gains and Losses and Amounts | Item | Amount (RMB) | Explanation | | :--- | :--- | :--- | | Gains and losses from disposal of non-current assets | -33,857.52 | Primarily due to losses from disposal of fixed assets | | Government grants recognized in current profit or loss | 7,885,201.56 | Primarily due to government special grants received during the reporting period | | Fair value changes and disposal gains/losses from financial assets and liabilities held by non-financial enterprises, excluding effective hedging activities related to normal business operations | 13,908,912.72 | Primarily due to investment income from financial assets held for trading | | Other non-operating income and expenses apart from the above | -631,315.86 | Primarily due to public welfare donation expenses | | Other profit and loss items meeting the definition of non-recurring gains and losses | 415,146.68 | Includes individual income tax handling fee refunds, additional input VAT deductions, and directly reduced VAT | | Less: Income tax impact | 4,424,053.78 | | | Impact on minority interests (after tax) | 36,727.24 | | | **Total** | **17,083,306.56** | | Part III Management Discussion and Analysis This section provides an in-depth analysis of the company's business operations, financial performance, core competencies, and risk factors [I. Main Business Activities During the Reporting Period](index=10&type=section&id=I.%20Main%20Business%20Activities%20During%20the%20Reporting%20Period) The company specializes in R&D, production, and sales of surgical medical devices, expanding into a platform-based group with significant growth in electric endoscopic stapler sales (**347.87%**) and overseas open stapler sales (**28.70%**) - The company primarily engages in the R&D, production, and sales of surgical medical devices, represented by staplers, and has developed into a platform-based group company covering multiple categories of surgical equipment and medical consumables[16](index=16&type=chunk) - During the reporting period, the sales revenue of the company's electric endoscopic stapler products increased by **347.87%** year-on-year, accounting for **29.82%** of stapler product operating revenue, a year-on-year increase of **22.38%**[16](index=16&type=chunk) - Overseas sales of open staplers significantly grew, driving a **28.70%** year-on-year increase in overall open stapler sales, accounting for **23.02%** of stapler product operating revenue[16](index=16&type=chunk) [1. Company's Main Business](index=10&type=section&id=1.%20Company's%20Main%20Business) The company primarily engages in the R&D, production, and sales of surgical medical devices, expanding its product lines through organic growth and external expansion - The company primarily engages in the R&D, production, and sales of surgical medical devices, represented by staplers[16](index=16&type=chunk) - Through organic growth and external expansion, the company continuously expands and extends its product lines, evolving from agency sales to a platform-based group company covering multiple categories of surgical equipment and medical consumables[16](index=16&type=chunk) [2. Main Products and Uses](index=10&type=section&id=2.%20Main%20Products%20and%20Uses) The company's product portfolio includes self-developed surgical staplers and equipment, alongside agency sales of other medical devices and consumables - The company's self-developed and manufactured products include endoscopic staplers (electric and manual), open staplers, stapler components, and surgical equipment (such as electric hydraulic operating tables, surgical shadowless lamps, pendant bridges, and delivery beds)[16](index=16&type=chunk)[17](index=17&type=chunk) - The company's agency sales products are categorized into medical equipment (such as surgical shadowless lamps, operating tables, monitors, ventilators) and low-value consumables (such as blood collection tubes, catheters, blood glucose test strips)[18](index=18&type=chunk) - During the reporting period, sales of the company's self-developed and manufactured surgical equipment accounted for **94.02%** of total sales, a year-on-year increase of **4.27%**, indicating a steady improvement in independent production and sales capabilities[18](index=18&type=chunk) [3. Company's Main Business Model](index=11&type=section&id=3.%20Company's%20Main%20Business%20Model) The company operates with centralized procurement, "production-to-order" manufacturing, and a dual sales model of distribution and direct sales - Procurement models are divided into raw and auxiliary material procurement (centralized and unified procurement, qualified supplier management) and agency business procurement (annual agency agreements, procurement based on demand and forecasts)[18](index=18&type=chunk) - The production model is "production-to-order with appropriate inventory," possessing full industry chain production capabilities for staplers, with outsourced processing mainly for non-core links such as sterilization and some component processing[19](index=19&type=chunk) - Sales models are divided into distribution (traditional distribution, two-invoice system distribution, secondary distribution) and direct sales (primarily for stapler components, molds, and assemblies)[19](index=19&type=chunk)[20](index=20&type=chunk)[21](index=21&type=chunk) [4. Industry Overview](index=12&type=section&id=4.%20Industry%20Overview) The global and Chinese medical device markets, particularly for staplers and endoscopic staplers, show strong growth, with the company actively pursuing technological advancements and market certifications - The global medical device market continues to grow, projected to reach **$913 billion** by 2030, with a compound annual growth rate of **6.18%** from 2022 to 2030[21](index=21&type=chunk) - China's medical device market has become the world's second-largest, projected to grow to **RMB 1,652 billion** by 2030, with a compound annual growth rate of **7.3%** from 2022 to 2030[21](index=21&type=chunk) - The stapler market continues to show positive development, with the global stapler market projected to grow to **$12.93 billion** by 2030, and the Chinese stapler market projected to grow to **RMB 20.5 billion** by 2030[22](index=22&type=chunk) - The endoscopic stapler market is experiencing rapid demand growth with significant import substitution potential; electric endoscopic staplers are cutting-edge products with high technological content[23](index=23&type=chunk) - The company has achieved technological R&D breakthroughs in endoscopic staplers, being one of the earliest domestic manufacturers to apply "unequal height staple" technology and participating in industry standard drafting[23](index=23&type=chunk) - As of the end of the reporting period, the company has obtained **44** medical device registration certificates and filing credentials (**4** Class I, **39** Class II, **1** Class III), and has received certifications from multiple countries including US FDA, Brazil ANVISA, and South Korea KFDA[23](index=23&type=chunk) [II. Analysis of Core Competencies](index=17&type=section&id=II.%20Analysis%20of%20Core%20Competencies) The company's core strengths lie in its complete industry chain, robust R&D, extensive marketing, growing brand, unique location, strict quality control, and experienced management - The company has achieved a full industry chain layout in surgical staplers, from product R&D and design, mold development, precision component processing, and production assembly to downstream sales[28](index=28&type=chunk) - As of the end of the reporting period, the company has obtained **243** patents, including **54** invention patents, and has made breakthroughs in innovative products such as electric endoscopic staplers and disposable electric ligation staplers[28](index=28&type=chunk) - The company has established a nationwide sales network centered in the Yangtze River Delta, covering multiple core cities and large tertiary hospitals, with **98** new distributors added during the reporting period[29](index=29&type=chunk) - The company actively participates in domestic and international academic forums and clinical training courses to enhance brand awareness and influence; its subsidiary Weike Medical collaborated with Xiangya Hospital of Central South University to establish the "Minimally Invasive Technology Innovation and Surgical Physician Training Joint Research Center" project[30](index=30&type=chunk) - Changzhou City, where the company is located, is an important production base for domestic staplers, offering geographical advantages that facilitate industry exchanges and cooperation[30](index=30&type=chunk) - The company has established a complete and comprehensive quality management system based on the ISO13485 quality management system and strictly adhering to regulations and standards such as the "Good Manufacturing Practices for Medical Devices"[30](index=30&type=chunk) - The management teams of the company and its subsidiaries possess extensive experience in the medical device industry and team management, with a stable core management team and good coordination with subsidiaries at all levels[30](index=30&type=chunk) [III. Analysis of Main Business](index=18&type=section&id=III.%20Analysis%20of%20Main%20Business) Main business analysis reveals a **5.82%** increase in operating revenue but a **4.71%** decrease in net profit, with stapler business having the highest revenue share and a **68.55%** gross profit margin Year-on-Year Changes in Key Financial Data | Indicator | Current Reporting Period (RMB) | Prior Year Period (RMB) | Year-on-Year Change | Reason for Change | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 213,553,049.86 | 201,802,103.61 | 5.82% | | | Operating Cost | 111,536,743.85 | 104,037,290.33 | 7.21% | | | Selling Expenses | 22,621,178.59 | 19,760,159.63 | 14.48% | | | Administrative Expenses | 34,648,528.09 | 29,997,318.49 | 15.51% | | | Financial Expenses | -2,711,325.82 | -6,134,605.68 | 55.80% | Primarily due to decreased interest income | | R&D Investment | 9,723,871.09 | 13,227,443.69 | -26.49% | | Products or Services Accounting for Over 10% of Revenue | By Product or Service | Operating Revenue (RMB) | Operating Cost (RMB) | Gross Profit Margin | Year-on-Year Change in Operating Revenue | Year-on-Year Change in Operating Cost | Year-on-Year Change in Gross Profit Margin | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Staplers | 90,752,358.01 | 28,546,112.45 | 68.55% | 12.15% | 17.88% | -1.53% | | Medical Equipment | 35,538,703.90 | 23,682,749.90 | 33.36% | -23.56% | -23.05% | -0.45% | | Low-Value Consumables | 26,109,683.81 | 17,298,327.95 | 33.75% | 15.87% | 20.57% | -2.58% | | Stapler Components | 57,901,294.22 | 39,464,849.74 | 31.84% | 16.70% | 18.99% | -1.31% | [IV. Analysis of Non-Core Business](index=19&type=section&id=IV.%20Analysis%20of%20Non-Core%20Business) Non-core business analysis shows investment income, mainly from bank wealth management, as the largest contributor to total profit, despite negative fair value change losses Impact of Non-Core Business on Total Profit | Item | Amount (RMB) | Proportion of Total Profit | Explanation of Formation Reason | Is it Sustainable | | :--- | :--- | :--- | :--- | :--- | | Investment Income | 18,250,206.02 | 32.22% | Primarily due to investment income from bank wealth management products | No | | Fair Value Change Gains and Losses | -4,461,677.91 | -7.88% | Primarily due to changes in gains from financial assets held for trading | No | | Asset Impairment | 138,752.51 | 0.24% | Primarily due to provisions for inventory write-downs and contract asset impairment losses | No | | Non-Operating Income | 54,082.37 | 0.10% | Primarily due to compensation and fine income | No | | Non-Operating Expenses | 685,398.23 | 1.21% | Primarily due to public welfare donation expenses | No | [V. Analysis of Assets and Liabilities](index=19&type=section&id=V.%20Analysis%20of%20Assets%20and%20Liabilities) Analysis of assets and liabilities shows a significant decrease in monetary funds due to wealth management purchases and a substantial increase in construction in progress from fundraising project investments Significant Changes in Asset Composition | Item | Amount at End of Current Reporting Period (RMB) | Proportion of Total Assets | Amount at End of Prior Year (RMB) | Proportion of Total Assets | Change in Proportion | Explanation of Significant Change | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Monetary Funds | 200,288,963.78 | 8.44% | 568,855,578.18 | 23.77% | -15.33% | Primarily due to increased purchases of wealth management products with monetary funds during the period | | Construction in Progress | 104,930,060.26 | 4.42% | 37,358,470.21 | 1.56% | 2.86% | Primarily due to increased investment in fundraising projects during the period | | Right-of-Use Assets | 2,506,764.59 | 0.11% | | | 0.11% | Primarily due to subsidiary Sanfeng Original leasing factory buildings externally during the period | | Short-Term Borrowings | 13,729,263.65 | 0.58% | 2,200,000.00 | 0.09% | 0.49% | Primarily due to increased bank borrowings during the period | | Contract Liabilities | 7,403,350.87 | 0.31% | 5,615,087.78 | 0.23% | 0.08% | Primarily due to increased advance receipts during the period | | Lease Liabilities | 2,061,891.46 | 0.09% | | | 0.09% | Primarily due to subsidiary Sanfeng Original leasing factory buildings externally during the period | Assets and Liabilities Measured at Fair Value | Item | Beginning Balance (RMB) | Fair Value Change Gains and Losses for the Period (RMB) | Amount Purchased During the Period (RMB) | Amount Sold During the Period (RMB) | Ending Balance (RMB) | | :--- | :--- | :--- | :--- | :--- | :--- | | Financial Assets Held for Trading | 674,291,095.76 | -4,461,677.91 | 1,613,500,000.00 | 1,332,000,000.00 | 951,329,417.85 | | Investments in Other Equity Instruments | | | 6,000,000.00 | | 6,000,000.00 | | **Subtotal of Financial Assets** | **674,291,095.76** | **-4,461,677.91** | **1,619,500,000.00** | **1,332,000,000.00** | **957,329,417.85** | - As of the end of the reporting period, the company's restricted monetary funds amounted to **RMB 1,373,735.00** for letter of guarantee deposits[37](index=37&type=chunk) [VI. Analysis of Investment Status](index=20&type=section&id=VI.%20Analysis%20of%20Investment%20Status) Investment analysis covers fair value financial assets, raised fund utilization (**RMB 144.5397 million** invested this period, **RMB 315.8131 million** cumulatively), and entrusted wealth management totaling **RMB 1,142.1 million** Financial Assets Measured at Fair Value | Asset Category | Initial Investment Cost (RMB) | Amount Purchased During Reporting Period (RMB) | Amount Sold During Reporting Period (RMB) | Ending Balance (RMB) | Source of Funds | | :--- | :--- | :--- | :--- | :--- | :--- | | Funds | | 6,000,000.00 | | 6,000,000.00 | Own Funds | Overall Use of Raised Funds | Indicator | Amount (RMB 10,000) | | :--- | :--- | | Total Raised Funds | 110,416.06 | | Total Raised Funds Invested During Reporting Period | 14,453.97 | | Cumulative Total Raised Funds Invested | 31,581.31 | | Cumulative Amount of Raised Funds with Changed Use | 19,462.15 | | Proportion of Cumulative Raised Funds with Changed Use | 17.63% | - As of June 30, 2024, the company used **RMB 144.5397 million** of raised funds this year, with a cumulative use of **RMB 315.8131 million**, and an unused balance of **RMB 686.9096 million**[40](index=40&type=chunk) Overview of Entrusted Wealth Management | Specific Type | Source of Entrusted Wealth Management Funds | Amount of Entrusted Wealth Management Occurred (RMB 10,000) | Unmatured Balance (RMB 10,000) | | :--- | :--- | :--- | :--- | | Bank Wealth Management Products | Own Funds | 23,210 | 5,660 | | Bank Wealth Management Products | Raised Funds | 67,000 | 64,500 | | Brokerage Wealth Management Products | Own Funds | 24,000 | 24,000 | | **Total** | | **114,210** | **94,160** | - The company had no derivative investments or entrusted loans during the reporting period[49](index=49&type=chunk)[50](index=50&type=chunk) [VII. Significant Asset and Equity Sales](index=25&type=section&id=VII.%20Significant%20Asset%20and%20Equity%20Sales) The company did not engage in any significant asset or equity sales during the reporting period - The company did not sell any significant assets during the reporting period[51](index=51&type=chunk) - The company did not sell any significant equity during the reporting period[52](index=52&type=chunk) [VIII. Analysis of Major Holding and Participating Companies](index=25&type=section&id=VIII.%20Analysis%20of%20Major%20Holding%20and%20Participating%20Companies) Major subsidiaries Weike Medical and Zihang Precision performed well, with Weike's electric endoscopic stapler sales up **347.87%** and Zihang's revenue up **19.78%** Financial Status of Major Subsidiaries | Company Name | Company Type | Main Business | Registered Capital (RMB 10,000) | Total Assets (RMB 10,000) | Net Assets (RMB 10,000) | Operating Revenue (RMB 10,000) | Operating Profit (RMB 10,000) | Net Profit (RMB 10,000) | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Changzhou Weike Medical Devices Co., Ltd. | Subsidiary | R&D, production, and sales of surgical stapler products | 500.00 | 22,871.57 | 7,911.61 | 9,074.36 | 3,181.14 | 2,741.55 | | Jiangsu Zihang Precision Hardware Co., Ltd. | Subsidiary | R&D, design, mold development, production, and sales of surgical stapler components and assemblies | 500.00 | 32,432.21 | 23,205.08 | 8,467.71 | 1,619.08 | 1,448.72 | - Weike Medical's electric endoscopic stapler product sales revenue increased by **347.87%** year-on-year during the reporting period, accounting for **29.82%** of the current period's stapler product operating revenue[54](index=54&type=chunk) - Zihang Precision's operating revenue for the reporting period was **RMB 84.6771 million**, a **19.78%** increase year-on-year, achieving a net profit of **RMB 14.4872 million**, a **29.14%** increase year-on-year[55](index=55&type=chunk) [IX. Information on Structured Entities Controlled by the Company](index=26&type=section&id=IX.%20Information%20on%20Structured%20Entities%20Controlled%20by%20the%20Company) The company did not control any structured entities during the reporting period - The company had no controlled structured entities during the reporting period[56](index=56&type=chunk) [X. Risks Faced by the Company and Countermeasures](index=26&type=section&id=X.%20Risks%20Faced%20by%20the%20Company%20and%20Countermeasures) This section details key risks, including volume-based procurement, technological changes, distributor management, agency rights, regulatory compliance, and goodwill impairment, outlining corresponding mitigation strategies - "Volume-based procurement" policies may lead to a significant drop in the company's product terminal prices; failure to win bids could result in decreased sales, potentially affecting the stapler components business[56](index=56&type=chunk) - Company countermeasures include closely monitoring policies, improving product quality, implementing a "price-for-volume" strategy, expanding market share, and increasing R&D investment while promoting intelligent manufacturing to reduce costs[57](index=57&type=chunk) - The company faces the risk of rapid technological iteration in the medical device industry; failure to update products promptly may lead to loss of market acceptance[58](index=58&type=chunk) - Company countermeasures involve increasing R&D investment, optimizing product structure, accelerating product R&D iteration, and focusing on developing forward-looking products such as electric endoscopic staplers, ultrasonic scalpels, and absorbable medical products[58](index=58&type=chunk) - The company primarily operates through a distribution model, facing distributor management risks where adverse changes in key distributors could impact sales revenue[59](index=59&type=chunk) - Company countermeasures include improving the distributor control system, strengthening evaluation and supervision, selecting high-quality distributors, and enhancing distributor work quality through business training and technical support[59](index=59&type=chunk) - The company's agency sales products face the risk of changes in agency operating rights; failure to continuously secure agency rights could lead to adverse impacts[60](index=60&type=chunk) - Company countermeasures include strictly adhering to contractual agreements, actively seeking new agency products, expanding agency categories, and carefully selecting suitable agency brands[60](index=60&type=chunk) - The company's products are classified as National Class I, II, and III medical devices, facing strict regulatory risks; failure to obtain renewal approvals or product non-compliance would result in adverse effects[61](index=61&type=chunk) - Company countermeasures involve strictly controlling product quality and actively organizing professional teams to ensure timely renewal of relevant qualification licenses before expiration[61](index=61&type=chunk) - As of June 30, 2024, the company's consolidated goodwill book value was **RMB 533.9309 million**, posing a risk of goodwill impairment due to factors such as policy changes and market competition[62](index=62&type=chunk) - Company countermeasures include continuously enriching subsidiary product lines, enhancing the driving force for sustainable business development, leveraging synergies, and focusing on and regularly assessing goodwill impairment risk points[62](index=62&type=chunk) [XI. Registration Form for Research, Communication, Interview, and Other Activities During the Reporting Period](index=28&type=section&id=XI.%20Registration%20Form%20for%20Research,%20Communication,%20Interview,%20and%20Other%20Activities%20During%20the%20Reporting%20Period) This section details investor engagement activities during the period, including dates, methods, participants, and key discussion topics - On May 15, 2024, the company participated in the 2023 Annual Performance Briefing via Panorama Network's "Investor Relations Interactive Platform," engaging in online discussions with investors regarding the company's annual production and operation, industry policy impacts, overseas markets, R&D status, and future development plans[63](index=63&type=chunk) [XII. Implementation of "Dual Improvement in Quality and Returns" Action Plan](index=28&type=section&id=XII.%20Implementation%20of%20%22Dual%20Improvement%20in%20Quality%20and%20Returns%22%20Action%20Plan) The company has not disclosed its "Dual Improvement in Quality and Returns" action plan announcement - The company has not disclosed an announcement regarding the "Dual Improvement in Quality and Returns" action plan[64](index=64&type=chunk) Part IV Corporate Governance This section details the company's corporate governance structure, including shareholder meetings, management changes, profit distribution, and incentive plans [I. Information on Annual and Extraordinary General Meetings Held During the Reporting Period](index=29&type=section&id=I.%20Information%20on%20Annual%20and%20Extraordinary%20General%20Meetings%20Held%20During%20the%20Reporting%20Period) This section details the annual and extraordinary general meetings held during the period, with resolutions duly convened and disclosed Shareholder Meetings During the Reporting Period | Session | Meeting Type | Investor Participation Rate | Date Held | Disclosure Date | Meeting Resolution | | :--- | :--- | :--- | :--- | :--- | :--- | | First Extraordinary General Meeting of 2024 | Extraordinary General Meeting | 31.96% | January 25, 2024 | January 25, 2024 | Specific content detailed in Juchao Information Network's "Resolution Announcement of the First Extraordinary General Meeting of 2024" (Announcement No.: 2024-006) | | 2023 Annual General Meeting | Annual General Meeting | 33.83% | May 13, 2024 | May 13, 2024 | Specific content detailed in Juchao Information Network's "Resolution Announcement of the 2023 Annual General Meeting" (Announcement No.: 2024-036) | - There were no instances during the reporting period where preferred shareholders with restored voting rights requested an extraordinary general meeting[66](index=66&type=chunk) [II. Changes in Directors, Supervisors, and Senior Management](index=29&type=section&id=II.%20Changes%20in%20Directors,%20Supervisors,%20and%20Senior%20Management) There were no changes in the company's directors, supervisors, or senior management during the reporting period - There were no changes in the company's directors, supervisors, and senior management during the reporting period; details can be found in the 2023 annual report[66](index=66&type=chunk) [III. Profit Distribution and Capital Reserve Conversion to Share Capital During the Reporting Period](index=29&type=section&id=III.%20Profit%20Distribution%20and%20Capital%20Reserve%20Conversion%20to%20Share%20Capital%20During%20the%20Reporting%20Period) The company plans no cash dividends, bonus shares, or capital reserve conversions for the half-year period - The company plans not to distribute cash dividends, bonus shares, or convert capital reserves into share capital for the half-year period[67](index=67&type=chunk) [IV. Implementation of Company Equity Incentive Plans, Employee Stock Ownership Plans, or Other Employee Incentive Measures](index=29&type=section&id=IV.%20Implementation%20of%20Company%20Equity%20Incentive%20Plans,%20Employee%20Stock%20Ownership%20Plans,%20or%20Other%20Employee%20Incentive%20Measures) The company's 2023 Restricted Stock Incentive Plan has been approved by all relevant bodies and is progressing as planned - The company's 2023 Restricted Stock Incentive Plan (Revised Draft) and its summary, along with the Implementation and Assessment Management Measures (Revised Draft), have been approved by the board of directors, supervisory board, and general meeting of shareholders[67](index=67&type=chunk)[68](index=68&type=chunk) - As of June 30, 2024, the company's 2023 Restricted Stock Incentive Plan is progressing in an orderly manner[68](index=68&type=chunk) - The company had no employee stock ownership plans or other employee incentive measures implemented during the reporting period[69](index=69&type=chunk) Part V Environmental and Social Responsibility This section outlines the company's commitment to environmental protection and its various social responsibility initiatives [I. Significant Environmental Issues](index=31&type=section&id=I.%20Significant%20Environmental%20Issues) The company is not a key polluting unit, received no environmental penalties, and strictly adheres to environmental laws and regulations - The company is not classified as a key polluting unit by environmental protection authorities[70](index=70&type=chunk) - During the reporting period, the company did not incur any penalties for violating environmental protection laws and regulations[70](index=70&type=chunk) [II. Social Responsibility](index=31&type=section&id=II.%20Social%20Responsibility) The company actively fulfills social responsibilities across investor rights, Party building, school-enterprise cooperation, employee welfare, supply chain, environmental sustainability, philanthropy, and international relations - The company fulfills information disclosure obligations through various means, safeguards the legitimate rights and interests of all shareholders, and adopts a stable cash dividend policy to protect the interests of small and medium investors[71](index=71&type=chunk) - The company's Party branch has **15** members, developed **9** new Party activists during the reporting period, and deeply studies and implements the Party's lines, principles, and policies[71](index=71&type=chunk) - The company has established a strategic partnership with Changzhou University, serving as its practical teaching and employment base, and actively participates in campus recruitment to strengthen talent development[71](index=71&type=chunk) - The company adheres to a people-oriented approach, focuses on enhancing employees' comprehensive abilities and career development, strictly complies with the "Labor Law" and "Labor Contract Law," and protects employees' legitimate rights and interests[72](index=72&type=chunk) - The company adheres to the principles of equality, voluntariness, and mutual benefit, builds and develops strategic partnerships with upstream and downstream entities, strictly controls product quality, and protects consumer interests[72](index=72&type=chunk) - The company highly values environmental protection, adheres to green, low-carbon, and sustainable development concepts, and its subsidiary Weike Medical was recognized as a Green Factory in Changzhou City[72](index=72&type=chunk) - The company actively participates in public welfare activities, donating **RMB 100,000** to the Wujin District Charity Federation and **RMB 500,000** to the Changzhou Charity Federation during the reporting period, and organizing employees to participate in public welfare activities[72](index=72&type=chunk) - The company emphasizes international market expansion; its subsidiary Weike Medical collaborated with Xiangya Hospital of Central South University to conduct international minimally invasive technology training programs and participated in the Dubai Arab Health Exhibition and the "Belt and Road" Thoracic Surgery Medical Quality Control Summit Forum[72](index=72&type=chunk) Part VI Significant Matters This section covers significant events, including commitments, related party transactions, litigation, and other material disclosures [I. Fulfilled and Overdue Unfulfilled Commitments by Actual Controllers, Shareholders, Related Parties, Acquirers, and the Company During the Reporting Period](index=33&type=section&id=I.%20Fulfilled%20and%20Overdue%20Unfulfilled%20Commitments%20by%20Actual%20Controllers,%20Shareholders,%20Related%20Parties,%20Acquirers,%20and%20the%20Company%20During%20the%20Reporting%20Period) This section details share lock-up commitments made during the IPO by actual controllers, shareholders, and related parties, with Wei Jiangang and Gong Aiqin's commitments fulfilled - The share lock-up commitments made by Wei Jiangang and Gong Aiqin during the initial public offering were fulfilled on May 30, 2024[73](index=73&type=chunk) - Commitments include not transferring shares within **12 months** from the company's listing date, and an automatic **6-month** extension of the lock-up period if the closing price falls below the offering price within **6 months** of listing[73](index=73&type=chunk) - While serving as a director or senior manager of the company, no more than **25%** of the total shares held by the individual may be transferred annually[73](index=73&type=chunk) [II. Non-Operating Occupation of Funds by Controlling Shareholders and Other Related Parties of the Listed Company](index=34&type=section&id=II.%20Non-Operating%20Occupation%20of%20Funds%20by%20Controlling%20Shareholders%20and%20Other%20Related%20Parties%20of%20the%20Listed%20Company) There was no non-operating occupation of funds by controlling shareholders or other related parties during the reporting period - There was no non-operating occupation of funds by controlling shareholders or other related parties of the listed company during the reporting period[74](index=74&type=chunk) [III. Irregular External Guarantees](index=34&type=section&id=III.%20Irregular%20External%20Guarantees) The company had no irregular external guarantees during the reporting period - The company had no irregular external guarantees during the reporting period[74](index=74&type=chunk) [IV. Appointment and Dismissal of Accounting Firms](index=34&type=section&id=IV.%20Appointment%20and%20Dismissal%20of%20Accounting%20Firms) The company's semi-annual financial report was not audited - The company's semi-annual report was not audited[74](index=74&type=chunk) [V. Explanation by the Board of Directors and Supervisory Board on "Non-Standard Audit Report" for the Current Reporting Period](index=34&type=section&id=V.%20Explanation%20by%20the%20Board%20of%20Directors%20and%20Supervisory%20Board%20on%20%22Non-Standard%20Audit%20Report%22%20for%20the%20Current%20Reporting%20Period) There was no non-standard audit report for the company during the reporting period - There was no non-standard audit report for the company during the reporting period[74](index=74&type=chunk) [VI. Explanation by the Board of Directors on "Non-Standard Audit Report" for the Prior Year](index=34&type=section&id=VI.%20Explanation%20by%20the%20Board%20of%20Directors%20on%20%22Non-Standard%20Audit%20Report%22%20for%20the%20Prior%20Year) There was no non-standard audit report for the company during the reporting period - There was no non-standard audit report for the company during the reporting period[74](index=74&type=chunk) [VII. Bankruptcy and Reorganization Matters](index=34&type=section&id=VII.%20Bankruptcy%20and%20Reorganization%20Matters) The company did not experience any bankruptcy or reorganization matters during the reporting period - The company did not experience any bankruptcy or reorganization matters during the reporting period[74](index=74&type=chunk) [VIII. Litigation Matters](index=34&type=section&id=VIII.%20Litigation%20Matters) The company had no major litigation, but other lawsuits totaling **RMB 3.1281 million** are ongoing, with some withdrawn or settled - The company had no significant lawsuits or arbitrations during the reporting period[75](index=75&type=chunk) Other Litigation Matters | Basic Information on Litigation (Arbitration) | Amount Involved (RMB 10,000) | Whether a Provision for Liabilities has been Formed | Progress of Litigation (Arbitration) | Outcome and Impact of Litigation (Arbitration) | Enforcement Status of Litigation (Arbitration) Judgment | | :--- | :--- | :--- | :--- | :--- | :--- | | Summary of Other Litigation Not Meeting Significant Litigation Disclosure Standards | 312.81 | No | Some cases have been withdrawn, some have been settled and executed, and some cases are yet to be heard | No significant impact | Some cases have been executed, and cases involving a remaining target amount of 281.67 million RMB are yet to be heard | [IX. Penalties and Rectification](index=34&type=section&id=IX.%20Penalties%20and%20Rectification) The company had no penalties or rectification situations during the reporting period - The company had no penalties or rectification situations during the reporting period[76](index=76&type=chunk) [X. Integrity Status of the Company, its Controlling Shareholder, and Actual Controller](index=35&type=section&id=X.%20Integrity%20Status%20of%20the%20Company,%20its%20Controlling%20Shareholder,%20and%20Actual%20Controller) There were no integrity issues concerning the company, its controlling shareholder, or actual controller during the reporting period - There were no integrity issues concerning the company's controlling shareholder or actual controller during the reporting period[77](index=77&type=chunk) [XI. Significant Related Party Transactions](index=35&type=section&id=XI.%20Significant%20Related%20Party%20Transactions) Significant related party transactions include **RMB 1.9968 million** in catering services from an actual controller-controlled entity, remaining within the approved limit Related Party Transactions Related to Daily Operations | Related Party | Relationship | Type of Related Party Transaction | Content of Related Party Transaction | Amount of Related Party Transaction (RMB 10,000) | Approved Transaction Limit (RMB 10,000) | Exceeded Approved Limit | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Changzhou Kaizhou Hotel Co., Ltd. | Enterprise controlled by the company's actual controller Wan Shiping | Purchase of Goods | Catering Services | 199.68 | 500 | No | - The company had no related party transactions involving asset or equity acquisitions or sales during the reporting period[78](index=78&type=chunk) - The company had no related party transactions involving joint external investments during the reporting period[79](index=79&type=chunk) - The company had no related party creditor-debtor relationships during the reporting period[80](index=80&type=chunk) - There were no deposits, loans, credit lines, or other financial transactions between the company and related financial companies, or between the company's controlled financial companies and related parties[81](index=81&type=chunk)[82](index=82&type=chunk) - The company had no other significant related party transactions during the reporting period[83](index=83&type=chunk) [XII. Significant Contracts and Their Performance](index=36&type=section&id=XII.%20Significant%20Contracts%20and%20Their%20Performance) Leasing activities involved **RMB 0.2042 million** in expenditures and **RMB 2.5 million** in income, with no single lease significantly impacting profit; no other major contracts or guarantees existed - During the reporting period, the company and its subsidiaries, as lessees, incurred cumulative lease expenditures totaling **RMB 0.2042 million**[83](index=83&type=chunk)[84](index=84&type=chunk) - The company and its subsidiaries, as lessors, cumulatively received rental income totaling **RMB 2.5 million** (including tax)[83](index=83&type=chunk) - The company had no leasing projects during the reporting period where the gains or losses accounted for more than **10%** of the company's total profit for the period[84](index=84&type=chunk) - The company had no significant guarantees during the reporting period[85](index=85&type=chunk) - The company had no major daily operating contracts during the reporting period[85](index=85&type=chunk) - The company had no other significant contracts during the reporting period[85](index=85&type=chunk) [XIII. Explanation of Other Significant Matters](index=37&type=section&id=XIII.%20Explanation%20of%20Other%20Significant%20Matters) There were no other significant matters requiring explanation during the reporting period - There were no other significant matters requiring explanation during the reporting period[85](index=85&type=chunk) [XIV. Significant Matters of Company Subsidiaries](index=37&type=section&id=XIV.%20Significant%20Matters%20of%20Company%20Subsidiaries) There were no significant matters concerning the company's subsidiaries during the reporting period - There were no significant matters concerning the company's subsidiaries during the reporting period[85](index=85&type=chunk) Part VII Share Changes and Shareholder Information This section details changes in the company's share capital, shareholder structure, and the status of share lock-ups and buybacks [I. Share Change Status](index=38&type=section&id=I.%20Share%20Change%20Status) This section details share changes, including the lifting of lock-ups on pre-IPO shares, actual tradable executive-locked shares, and the progress of the share repurchase plan Share Change Status | | Quantity Before This Change (shares) | Proportion | Increase/Decrease in This Change (+, -) Other (shares) | Subtotal (shares) | Quantity After This Change (shares) | Proportion | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | I. Restricted Shares | 32,175,434 | 32.12% | -181,250 | -181,250 | 31,994,184 | 31.94% | | Of which: Shares held by domestic natural persons | 27,420,434 | 27.37% | -181,250 | -181,250 | 27,239,184 | 27.19% | | II. Unrestricted Shares | 67,997,900 | 67.88% | +181,250 | +181,250 | 68,179,150 | 68.06% | | Of which: RMB Ordinary Shares | 67,997,900 | 67.88% | +181,250 | +181,250 | 68,179,150 | 68.06% | | III. Total Shares | 100,173,334 | 100.00% | 0 | 0 | 100,173,334 | 100.00% | - On May 31, 2024, **725,000** restricted shares held by **2** shareholders (Wei Jiangang, Gong Aiqin) from the company's pre-IPO issuance were released from lock-up, with an actual tradable quantity of **181,250** shares[86](index=86&type=chunk) - The company's share repurchase plan has been completed, with a cumulative repurchase of **1,492,651** shares, accounting for **1.4901%** of the total share capital, and a total transaction amount of **RMB 29,982,395.65**[87](index=87&type=chunk) Changes in Restricted Shares | Shareholder Name | Restricted Shares at Beginning of Period (shares) | Restricted Shares Released During Period (shares) | Restricted Shares Increased During Period (shares) | Restricted Shares at End of Period (shares) | Reason for Restriction | Planned Release Date | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Wan Shiping | 25,052,934 | 0 | 0 | 25,052,934 | Pre-IPO Restricted Shares | May 30, 2026 | | Wei Jiangang | 540,000 | 540,000 | 405,000 | 405,000 | Pre-IPO Restricted Shares, Executive Locked Shares | During tenure as director, supervisor, or senior executive, 25% of total shares held are released annually, with the remaining 75% automatically locked | | Gong Aiqin | 185,000 | 185,000 | 138,750 | 138,750 | Pre-IPO Restricted Shares, Executive Locked Shares | During tenure as director, supervisor, or senior executive, 25% of total shares held are released annually, with the remaining 75% automatically locked | [II. Securities Issuance and Listing Status](index=40&type=section&id=II.%20Securities%20Issuance%20and%20Listing%20Status) The company had no securities issuance or listing activities during the reporting period - The company had no securities issuance or listing activities during the reporting period[88](index=88&type=chunk) [III. Number of Shareholders and Shareholding Status](index=40&type=section&id=III.%20Number%20of%20Shareholders%20and%20Shareholding%20Status) At period-end, the company had **12,276** ordinary shareholders, with Wan Shiping as the largest shareholder, holding **25.01%** - The total number of ordinary shareholders at the end of the reporting period was **12,276** households[88](index=88&type=chunk) Top 10 Shareholders' Shareholding Status | Shareholder Name | Shareholder Nature | Shareholding Proportion | Number of Shares Held at End of Reporting Period (shares) | Number of Restricted Shares Held (shares) | Number of Unrestricted Shares Held (shares) | | :--- | :--- | :--- | :--- | :--- | :--- | | Wan Shiping | Domestic Natural Person | 25.01% | 25,052,934 | 25,052,934 | 0 | | Jiang Shihua | Domestic Natural Person | 5.06% | 5,070,000 | 0 | 5,070,000 | | Changzhou Kaizhou Investment Management Co., Ltd. | Domestic Non-State-Owned Legal Person | 4.49% | 4,500,000 | 4,500,000 | 0 | | Wang Hailong | Domestic Natural Person | 4.30% | 4,310,000 | 0 | 4,310,000 | | Suzhou Jifeng Equity Investment Partnership (Limited Partnership) | Domestic Non-State-Owned Legal Person | 4.13% | 4,142,000 | 0 | 4,142,000 | - Wan Shiping is Wan Zhengyuan's father, and Changzhou Kaizhou Investment Management Co., Ltd. is a company controlled by Wan Shiping[88](index=88&type=chunk) [IV. Cumulative Pledged Shares of Controlling Shareholder or Largest Shareholder and Their Concerted Parties Reaching 80% of Their Total Holdings](index=42&type=section&id=IV.%20Cumulative%20Pledged%20Shares%20of%20Controlling%20Shareholder%20or%20Largest%20Shareholder%20and%20Their%20Concerted%20Parties%20Reaching%2080%25%20of%20Their%20Total%20Holdings) The company's controlling shareholder or largest shareholder and their concerted parties did not have cumulative pledged shares reaching **80%** of their total holdings - During the reporting period, there was no situation where the cumulative pledged shares of the controlling shareholder or largest shareholder and their concerted parties reached **80%** of their total holdings in the company[92](index=92&type=chunk) [V. Changes in Shareholdings of Directors, Supervisors, and Senior Management](index=42&type=section&id=V.%20Changes%20in%20Shareholdings%20of%20Directors,%20Supervisors,%20and%20Senior%20Management) There were no changes in the shareholdings of the company's directors, supervisors, or senior management during the reporting period - There were no changes in the shareholdings of the company's directors, supervisors, and senior management during the reporting period; details can be found in the 2023 annual report[92](index=92&type=chunk) [VI. Changes in Controlling Shareholder or Actual Controller](index=42&type=section&id=VI.%20Changes%20in%20Controlling%20Shareholder%20or%20Actual%20Controller) There were no changes in the company's controlling shareholder or actual controller during the reporting period - The company's controlling shareholder did not change during the reporting period[93](index=93&type=chunk) - The company's actual controller did not change during the reporting period[93](index=93&type=chunk) Part VIII Preferred Share Information This section confirms the absence of preferred shares in the company during the reporting period [The Company Had No Preferred Shares During the Reporting Period](index=43&type=section&id=The%20Company%20Had%20No%20Preferred%20Shares%20During%20the%20Reporting%20Period) The company had no preferred shares during the reporting period - The company had no preferred shares during the reporting period[94](index=94&type=chunk) Part IX Bond Information This section confirms the absence of bonds issued by the company during the reporting period [The Company Had No Bonds During the Reporting Period](index=44&type=section&id=The%20Company%20Had%20No%20Bonds%20During%20the%20Reporting%20Period) The company had no bonds during the reporting period - The company had no bonds during the reporting period[95](index=95&type=chunk) Part X Financial Report This section presents the company's unaudited semi-annual financial statements and detailed notes on accounting policies, taxes, and financial items [I. Audit Report](index=45&type=section&id=I.%20Audit%20Report) The company's semi-annual financial report was not audited - The company's semi-annual financial report was not audited[96](index=96&type=chunk) [II. Financial Statements](index=45&type=section&id=II.%20Financial%20Statements) This section presents the company's consolidated and parent company financial statements for H1 2024, detailing financial position and operating results - This section includes the consolidated balance sheet, parent company balance sheet, consolidated income statement, parent company income statement, consolidated cash flow statement, parent company cash flow statement, consolidated statement of changes in owners' equity, and parent company statement of changes in owners' equity[97](index=97&type=chunk)[100](index=100&type=chunk)[103](index=103&type=chunk)[106](index=106&type=chunk)[109](index=109&type=chunk)[111](index=111&type=chunk)[113](index=113&type=chunk)[119](index=119&type=chunk) [1. Consolidated Balance Sheet](index=45&type=section&id=1.%20Consolidated%20Balance%20Sheet) The consolidated balance sheet provides a snapshot of the company's assets, liabilities, and equity at the end of the reporting period Key Data from Consolidated Balance Sheet | Item | Ending Balance (RMB) | Beginning Balance (RMB) | | :--- | :--- | :--- | | Monetary Funds | 200,288,963.78 | 568,855,578.18 | | Financial Assets Held for Trading | 957,329,417.85 | 674,291,095.76 | | Accounts Receivable | 92,219,159.77 | 97,097,633.66 | | Inventories | 108,616,171.22 | 102,751,487.49 | | Total Assets | 2,373,152,059.47 | 2,393,581,909.51 | | Short-Term Borrowings | 13,729,263.65 | 2,200,000.00 | | Total Liabilities | 168,038,096.96 | 147,371,481.33 | | Total Equity Attributable to Parent Company Owners | 2,197,841,813.21 | 2,238,716,685.61 | | Total Liabilities and Owners' Equity | 2,373,152,059.47 | 2,393,581,909.51 | [2. Parent Company Balance Sheet](index=47&type=section&id=2.%20Parent%20Company%20Balance%20Sheet) The parent company balance sheet details the assets, liabilities, and equity of the parent entity at the end of the reporting period Key Data from Parent Company Balance Sheet | Item | Ending Balance (RMB) | Beginning Balance (RMB) | | :--- | :--- | :--- | | Monetary Funds | 139,759,314.59 | 478,991,880.99 | | Financial Assets Held for Trading | 874,730,210.96 | 643,146,679.46 | | Accounts Receivable | 34,240,727.97 | 41,077,023.64 | | Long-Term Equity Investments | 844,303,743.52 | 843,755,712.49 | | Total Assets | 2,169,296,783.21 | 2,196,598,820.08 | | Short-Term Borrowings | 11,729,263.65 | 200,000.00 | | Total Liabilities | 54,919,634.32 | 40,753,476.84 | | Total Owners' Equity | 2,114,377,148.89 | 2,155,845,343.24 | | Total Liabilities and Owners' Equity | 2,169,296,783.21 | 2,196,598,820.08 | [3. Consolidated Income Statement](index=49&type=section&id=3.%20Consolidated%20Income%20Statement) The consolidated income statement presents the company's revenues, expenses, and net profit for the reporting period Key Data from Consolidated Income Statement | Item | H1 2024 (RMB) | H1 2023 (RMB) | | :--- | :--- | :--- | | Total Operating Revenue | 213,553,049.86 | 201,802,103.61 | | Total Operating Cost | 178,057,565.42 | 162,689,502.68 | | Operating Profit | 57,273,796.95 | 61,370,309.81 | | Total Profit | 56,642,481.09 | 61,465,963.24 | | Net Profit | 47,458,216.10 | 51,837,595.49 | | Net Profit Attributable to Parent Company Shareholders | 47,679,809.37 | 50,034,885.79 | | Basic Earnings Per Share (RMB/share) | 0.48 | 0.50 | | Diluted Earnings Per Share (RMB/share) | 0.48 | 0.50 | [4. Parent Company Income Statement](index=51&type=section&id=4.%20Parent%20Company%20Income%20Statement) The parent company income statement outlines the parent entity's revenues, expenses, and net profit for the reporting period Key Data from Parent Company Income Statement | Item | H1 2024 (RMB) | H1 2023 (RMB) | | :--- | :--- | :--- | | Operating Revenue | 54,114,737.28 | 51,228,470.82 | | Operating Cost | 37,729,288.86 | 33,775,940.80 | | Operating Profit | 51,095,859.74 | 51,542,653.24 | | Total Profit | 50,410,787.19 | 51,531,985.28 | | Net Profit | 46,636,487.42 | 45,880,092.63 | [5. Consolidated Cash Flow Statement](index=52&type=section&id=5.%20Consolidated%20Cash%20Flow%20Statement) The consolidated cash flow statement details the company's cash inflows and outflows from operating, investing, and financing activities Key Data from Consolidated Cash Flow Statement | Item | H1 2024 (RMB) | H1 2023 (RMB) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 70,317,683.91 | 64,035,419.50 | | Net Cash Flow from Investing Activities | -360,652,953.53 | -498,667,660.09 | | Net Cash Flow from Financing Activities | -76,984,024.48 | -70,014,460.95 | | Net Increase in Cash and Cash Equivalents | -367,370,694.40 | -504,422,303.09 | | Cash and Cash Equivalents at End of Period | 197,887,388.78 | 607,222,023.01 | [6. Parent Company Cash Flow Statement](index=53&type=section&id=6.%20Parent%20Company%20Cash%20Flow%20Statement) The parent company cash flow statement presents the parent entity's cash flows from operating, investing, and financing activities Key Data from Parent Company Cash Flow Statement | Item | H1 2024 (RMB) | H1 2023 (RMB) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | -74,890,237.22 | -10,476,637.75 | | Net Cash Flow from Investing Activities | -183,982,221.10 | -434,528,684.43 | | Net Cash Flow from Financing Activities | -79,164,188.08 | -70,242,283.48 | | Net Increase in Cash and Cash Equivalents | -338,036,646.40 | -515,247,605.66 | | Cash and Cash Equivalents at End of Period | 138,731,474.59 | 522,962,834.75 | [7. Consolidated Statement of Changes in Owners' Equity](index=54&type=section&id=7.%20Consolidated%20Statement%20of%20Changes%20in%20Owners'%20Equity) The consolidated statement of changes in owners' equity tracks the movements in the company's equity components over the reporting period - Total comprehensive income attributable to parent company owners for the current period was **RMB 47,679,809.37**[114](index=114&type=chunk) - Owners' contributions and capital reductions resulted in a **RMB 28,741,711.97** decrease in equity attributable to parent company owners for the current period[114](index=114&type=chunk) - Profit distribution for the current period resulted in a **RMB 59,812,969.80** decrease in equity attributable to parent company owners, primarily including the appropriation of **RMB 4,663,648.74** for surplus reserves and **RMB 59,812,969.80** distributed to owners[114](index=114&type=chunk)[115](index=115&type=chunk) [8. Parent Company Statement of Changes in Owners' Equity](index=58&type=section&id=8.%20Parent%20Company%20Statement%20of%20Changes%20in%20Owners'%20Equity) The parent company statement of changes in owners' equity details the movements in the parent entity's equity components during the reporting period - Total comprehensive income for the parent company in the current period was **RMB 46,636,487.42**[120](index=120&type=chunk) - Owners' contributions and capital reductions resulted in a **RMB 28,741,711.97** decrease in owners' equity for the current period[120](index=120&type=chunk) - Profit distribution for the current period resulted in a **RMB 59,362,969.80** decrease in owners' equity, primarily including the appropriation of **RMB 4,663,648.74** for surplus reserves and **RMB 59,362,969.80** distributed to owners[120](index=120&type=chunk)[121](index=121&type=chunk) [III. Company Overview](index=62&type=section&id=III.%20Company%20Overview) This section provides fundamental company information, including establishment, listing, share capital, registered capital, main business, and actual controllers - Jiangsu Dongxing Smart Medical Technology Co., Ltd. was established on February 21, 2001, and listed on the Shenzhen Stock Exchange on November 30, 2022[125](index=125&type=chunk) - As of June 30, 2024, the company's cumulative issued share capital totaled **100,173,334** shares, with a registered capital of **RMB 100,173,334.00**[125](index=125&type=chunk) - The company's main business activities include the R&D, production, sales, and related services of Class I, II, and III medical devices, with Wan Shiping and Wan Zhengyuan (father and son) as the actual controllers[125](index=125&type=chunk) [IV. Basis of Financial Statement Preparation](index=62&type=section&id=IV.%20Basis%20of%20Financial%20Statement%20Preparation) The financial statements are prepared under Enterprise Accounting Standards and CSRC regulations, based on a going concern assumption - These financial statements are prepared in accordance with the "Enterprise Accounting Standards" issued by the Ministry of Finance and the relevant provisions of the China Securities Regulatory Commission's "Information Disclosure Rules for Companies Issuing Securities Publicly No. 15 – General Provisions for Financial Reports"[126](index=126&type=chunk) - These financial statements are prepared on a going concern basis, and the company has the ability to continue as a going concern for at least **12 months** from the end of the reporting period[127](index=127&type=chunk) [V. Significant Accounting Policies and Estimates](index=62&type=section&id=V.%20Significant%20Accounting%20Policies%20and%20Estimates) This section outlines the company's significant accounting policies and estimates, ensuring financial information accuracy and comparability across various aspects, including lease accounting - The company has formulated specific accounting policies and estimates for transactions and matters such as fixed asset depreciation, intangible asset amortization, and revenue recognition, based on its actual production and operational characteristics[128](index=128&type=chunk) - These financial statements comply with the requirements of the Enterprise Accounting Standards issued by the Ministry of Finance, truly and completely reflecting the company's financial position, operating results, and cash flows[129](index=129&type=chunk) - The company has detailed accounting policies and measurement methods for financial instruments, inventories, long-term equity investments, fixed assets, intangible assets, revenue recognition, government grants, and leases[141](index=141&type=chunk)[154](index=154&type=chunk)[159](index=159&type=chunk)[164](index=164&type=chunk)[170](index=170&type=chunk)[191](index=191&type=chunk)[194](index=194&type=chunk)[197](index=197&type=chunk) [VI. Taxes](index=84&type=section&id=VI.%20Taxes) This section details the company's and its subsidiaries' main tax categories, rates, and preferential tax policies, including VAT, Urban Maintenance and Construction Tax, and EIT Main Tax Categories and Rates | Tax Category | Tax Basis | Tax Rate | | :--- | :--- | :--- | | Value-Added Tax (VAT) | Sales of goods and taxable services calculated according to tax laws, with input VAT deducted, the difference being VAT payable | 13%, 9%, 6% | | Urban Maintenance and Construction Tax | Calculated based on actual VAT paid | 7% | | Enterprise Income Tax (EIT) | Calculated based on taxable income | 25%, 20%, 15% | - Subsidiaries Changzhou Weike Medical Devices Co., Ltd. and Jiangsu Zihang Precision Hardware Co., Ltd. are subject to an Enterprise Income Tax rate of **15%** in 2024 due to their high-tech enterprise certificates[203](index=203&type=chunk) - Subsidiaries Suzhou Sanfeng Original Medical Technology Co., Ltd., Sanfeng Dongxing Medical Equipment (Jiangsu) Co., Ltd., and Changzhou Changheng Precision Mold Technology Co., Ltd. qualify as small and micro enterprises, enjoying a preferential Enterprise Income Tax rate of **20%**[203](index=203&type=chunk) [VII. Notes to Consolidated Financial Statement Items](index=85&type=section&id=VII.%20Notes%20to%20Consolidated%20Financial%20Statement%20Items) This section provides detailed notes on consolidated financial statement items, in

证券代码：301290 证券简称：东星医疗 公告编号：2024-070 （二）2023年6月9日至2023年6月18日，公司对本次激励计划授予激励对象 的姓名和职务在公司内部进行了公示。在公示期内，公司监事会未收到与本次 激励计划授予激励对象有关的任何异议。2023年6月30日，公司披露了《江苏东 星智慧医疗科技股份有限公司监事会关于公司2023年限制性股票激励计划激励 对象名单的公示情况说明及核查意见》。 （三）2023年6月19日，公司召开第三届董事会第十二次会议和第三届监事 会第九次会议，会议审议通过了《关于公司<2023年限制性股票激励计划（草案 修订稿）>及其摘要的议案》《关于公司<2023年限制性股票激励计划实施考核 管理办法（修订稿）>的议案》等议案。公司独立董事就本次激励计划及本次修 订是否有利于公司的持续发展及是否存在损害公司及全体股东利益的情形发表 了独立意见。北京市天元律师事务所出具了《关于江苏东星智慧医疗科技股份 有限公司 2023年限制性股票激励计划（草案修订稿）的法律意见》。 （四）2023年7月5日，公司召开2023年第三次临时股东大会，审议并通过 了《关于公司<2023年限制性 ...

证券代码：301290 证券简称：东星医疗 公告编号：2024-062 江苏东星智慧医疗科技股份有限公司 关于稳定股价方案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 1、根据《公司首次公开发行股票并上市后三年内稳定股价的预案》（以下 简称"《稳定股价预案》"），江苏东星智慧医疗科技股份有限公司（以下简 称"公司"）拟采取董事（独立董事、不在公司领取薪酬的董事除外）和高级 管理人员增持公司股票的方式履行稳定股价义务。 2、在遵守所适用的法律、法规、规范性文件的前提下，根据《稳定股价预 案》，有增持义务的董事、高级管理人员应以不低于各自上一年度从公司取得 的税后薪酬的 20%的资金增持公司股份。单一会计年度内有增持义务的董事和 高级管理人员用以稳定股价的增持资金合计不超过其上一会计年度从公司取得 的税后薪酬的 50%。根据各位董事、高级管理人员的增持计划，公司董事长万 世平先生增持股份金额合计不低于 20.00 万元，董事、总经理魏建刚先生增持 股份金额合计不低于 20.00 万元，董事、副总经理、董事会秘书兼财务总监龚 爱琴女士增持股 ...

证券代码：301290 证券简称：东星医疗 公告编号：2024-059 江苏东星智慧医疗科技股份有限公司 关于董事会完成换届选举的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 江苏东星智慧医疗科技股份有限公司(以下简称"公司")于2024年7月12日 召开2024年第二次临时股东大会，审议通过了《关于公司董事会换届选举暨 选举公司第四届董事会非独立董事的议案》《关于公司董事会换届选举暨选 举第四届董事会独立董事的议案》，选举产生了万世平先生、魏建刚先生、 龚爱琴女士、万正元先生为公司第四届董事会非独立董事，选举产生了沈世娟 女士、朱旗先生、上官俊杰先生为公司第四届董事会独立董事，第四届董事会独 立董事薪酬（津贴）方案实行年薪制，津贴标准为6万元/年，不再另行发放其他 薪酬。上述7名董事共同组成公司第四届董事会，任期三年，任职期限自2024年 第二次临时股东大会审议通过之日起计算。 公司于2024年7月12日召开第四届董事会第一次会议，审议通过了《关于 选举公司第四届董事会董事长的议案》《关于选举公司第四届董事会专门委 员会委员的议案》，同意选举万世平先 ...

证券代码：301290 证券简称：东星医疗 公告编号：2024- 056 江苏东星智慧医疗科技股份有限公司 2024年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开的时间： （1）现场会议时间：2024年7月12日（星期五）下午2:30； （2）网络投票时间：通过深圳证券交易所交易系统投票的时间为2024年7月 12日上午9:15-9:25，9:30—11:30，下午13:00—15:00；通过深圳证券交易所互联 网投票系统投票的时间为2024年7月12日上午9:15至下午3:00的任意时间。 2、会议召开方式：本次股东大会采用现场投票与网络投票相结合的方式。 3、会议召开地点：江苏省常州市武进区长扬路24-4号公司会议室。 （二）会议出席情况 1、出席会议的总体情况 本次会议现场出席及网络出席的股东和股东代表共13人，代表股份 31,945,734股，占公司有表决权股份 ...